FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Nashington,	D.C. 20549
-------------	------------

STATEMENT	OF CHANGES I	N BENEFICIAL	OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Wallace Courtney				Kez	2. Issuer Name and Ticker or Trading Symbol Kezar Life Sciences, Inc. [KZR]							(Ch	elationship eck all appli X Directo	,) Pers	on(s) to Iss		
(Last)	(F	irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/15/2023								Officer below)	(give title		Other (s below)	pecify
C/O KEZAR LIFE SCIENCES, INC. 4000 SHORELINE COURT, SUITE 300				4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
(Street) SOUTH SAN FRANCISCO CA 94080			Bul	Dula 10h5 1(a) Transaction Indiana								Form filed by More than One Reporting Person						
(City)		tate)	(Zip)		 (Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Ins						ant to a con		on or written	plan th	nat is intende	d to	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				Execution Date,			Code (Ins	Transaction Disposed Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 a		Benefici Owned I	es ally Following	Form:	Direct Control of the	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code	v	Amount (A) or (D)		r Price	Transac	Reported Transaction(s) (Instr. 3 and 4)			instr. 4)			
		Т							uired, Dis , options					Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	4. Transact Code (In 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisal Expiration Date (Month/Day/Year			7. Title an Amount o Securities Underlyin Derivative (Instr. 3 an	f g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Exp Dat	piration te	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$2.64	06/15/2023			A		35,000		(1)	06/	/14/2033	Common Stock	35,000	\$0.00	35,000		D	

Explanation of Responses:

1. One-hundred percent (100%) of the shares subject to the option shall vest on 6/15/2024, subject to Reporting Person continuing to provide service through such date.

Remarks:

/s/ Marc Belsky, Attorney-in-

Fact

06/16/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.